Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Cell and gene therapy manufacturing

- PMLiVE

NICE wants more info on Novartis’ Xolair in chronic hives

Says company must provide more data on the drug's effectiveness

Novartis building

Novartis to deliver three million malaria treatments in Zambia

Part of Malaria No More’s Power of One campaign

Novartis building

Novartis faces FDA rejection for myeloma drug

Concerns over toxicity of panobinostat

- PMLiVE

Pfizer gets FDA nod for meningitis vaccine Trumenba

Ahead of Novartis’ rival drug Bexsero

Novartis building

Novartis sells flu vaccines business to CSL for $275m

Follows the Swiss pharma company's asset swap deals with GSK

Novartis building

FDA panel backs Novartis’ secukinumab for psoriasis

Drug has outperformed Amgen’s Enbrel in clinical trials

Novartis building

Novartis’ secukinumab has ‘consistent’ activity in psoriasis

Reinforces data that suggests drug is more effective than Amgen’s Enbrel

- PMLiVE

Novartis announces departures of three execs

Follows deals to sell divisions to GSK and Lilly

- PMLiVE

Novartis’ Bexsero triumphs at UK Prix Galien

The Awards also saw Janssen's Sirturo pick up the Orphan Drug prize

- PMLiVE

Boehringer Ingelheim promotes Debraj Dasgupta

He will lead on its global marketing and sales platforms

- PMLiVE

Novartis expands eyecare partnership with NHS

And wins new licence for Lucentis

- PMLiVE

Avastin safe in eye disease, says Cochrane

Recommends off-label use of Roche drug as cheaper alternative to Novartis’ Lucentis

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links